State of the neoadjuvant therapy for glioblastoma multiforme-Where do we stand?
Neurooncol Adv
; 6(1): vdae028, 2024.
Article
en En
| MEDLINE
| ID: mdl-38560349
ABSTRACT
Glioblastoma multiforme (GBM) is the most common malignant primary brain tumor in adults. Despite several investigations in this field, maximal safe resection followed by chemoradiotherapy and adjuvant temozolomide with or without tumor-treating fields remains the standard of care with poor survival outcomes. Many endeavors have failed to make a dramatic change in the outcomes of GBM patients. This study aimed to review the available strategies for newly diagnosed GBM in the neoadjuvant setting, which have been mainly neglected in contrast to other solid tumors.
Texto completo:
1
Bases de datos:
MEDLINE
Idioma:
En
Revista:
Neurooncol Adv
Año:
2024
Tipo del documento:
Article
País de afiliación:
Irán